1.26 USD
↘ 0.01 (0.79%)AT CLOSE (03:59 PM EST)
BioVie, Inc. Common Stock
BIVINASDAQ • USD
1.26
↗ 0.00 (0.00%)
POST MARKET (AS OF 05:41 PM EST)
Post Market
AS OF 05:41 PM EST
1.26
↗ 0.00 (0.00%)
Market: OPEN
BioVie, Inc. Common Stock (BIVI) trades at $1.26 per share. Both sides of the analysis point lower: technicals flash "Strong Sell" and fundamentals confirm with a "Sell" reading. This is driven by a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, negative Return on Equity, a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. Valuation metrics suggest BIVI is trading at a discount to its peers, earning an "Attractively Valued" rating.
Technical & fundamental data as of Nov 11, 2026.
Open?$1.28
High?$1.32
Low?$1.24
Prev. Close?$1.27
Volume?137.7K
Avg. Volume?667.8K
VWAP?$1.29
Rel. Volume?0.21x
Bid / Ask
Bid?$1.08 × 100
Ask?$1.50 × 100
Spread?$0.42
Midpoint?$1.29
Valuation & Ratios
Market Cap?13.6M
Shares Out?8.7M
Float?7.0M
Float %?82.5%
P/E Ratio?N/A
P/B Ratio?2.09
EPS?-$2.11
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
BioVie Inc is a clinical-stage company developing drug therapies for the treatment of neurological and neurodegenerative disorders and liver disease. Its therapeutic areas include Alzheimer's, Parkinson's, Long COVID, Ascites, Longevity, and Epigenetics. In liver disease, its investigational drug candidate BIV201 (continuous infusion terlipressin) was granted FDA Fast Track status and FDA Orphan Drug designation for ascites due to all etiologies except cancer. BIV201 is being evaluated as a treatment option for patients suffering from life-threatening complications of liver cirrhosis and ascites due to hepatitis, nonalcoholic steatohepatitis, and alcoholism.
Employees
13
Market Cap
13.6M
Industry
PHARMACEUTICAL PREPARATIONS
Website
Listed
2014-01-14
Address
680 W NYE LANE
CARSON CITY, NV 89703
Phone: 775-888-3162
CARSON CITY, NV 89703
Phone: 775-888-3162
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-3/3)
Medium-Term (Wave)?▼ Bearish(-3/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?3
Z-Score?0
Momentum?77
Short Sent.?35
Piotroski F-Score?0/9Weak
Altman Z-Score?-52.59Distress
Confidence?44%Low
Short InterestElevated
Short % of Float?8.45%Elevated
Short Interest?589.1K
Days to Cover?3.7
Free Float7.0M
Avg Daily Volume160.2K
Settlement Date2026-10-30
Financial Health
Current Ratio?2.40Strong
Quick Ratio?2.40Strong
Cash Ratio?1.78Strong
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score100/100
P/E?N/A▾
P/B?2.09CHEAP▾
Peers100
S&P72
P/S?N/A▾
P/FCF?N/A▾
EV/EBITDA?-0.3CHEAP▾
S&P97
EV/Sales?N/A▾
Returns & Efficiency
ROE?-346.0%WEAK▾
S&P3
ROA?-204.7%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$-18906399
Enterprise Value?$5.9M
Fundamentals ratios updated end of day